Mylan Institutional, Inc. (D.B.A. UDL Laboratories) FDA Record

Warning letters, Form 483s, inspections, recalls and 510(k) clearances

  • 1 Class I recall
  • No warning letters matched by name
Inspections 0 0 OAI
Recalls 22 1 Class I (5%)
Warning letters 0 None on file
510(k) clearances 0 None on file

Mylan Institutional, Inc. (D.B.A. UDL Laboratories) has 22 FDA recalls (1 Class I), 0 inspections, 0 510(k) clearances and 0 compliance actions on record. No FDA warning letter addressed to "Mylan Institutional, Inc. (D.B.A. UDL Laboratories)" is on file.

What these totals cover: FDA records filed under the name "Mylan Institutional, Inc. (D.B.A. UDL Laboratories)".

Latest recall
D-0860-2022 · Class II · Apr 1, 2022

Summary

Record counts and when each FDA source was last refreshed
RecordsCountLast refreshedSource as ofStatus
Recalls22 (1 Class I)Nov 15, 2026File dated Nov 10, 2026Current
510(k) clearances0Nov 15, 2026File dated Nov 9, 2026Current
Inspections0Nov 17, 2026Newest record Nov 9, 2026Current
Compliance actions0Nov 2, 2026Newest record Oct 29, 2026Current

FDA record by year

Mylan Institutional, Inc. (D.B.A. UDL Laboratories)'s FDA inspections, warning letters and recalls in each of the last 10 calendar years (2017 to 2026, 2026 so far).

Mylan Institutional, Inc. (D.B.A. UDL Laboratories): FDA recall records per year

2017: 0 inspections (0 OAI), 0 warning letters, 2 recall records (0 Class I) 2018: 0 inspections (0 OAI), 0 warning letters, 3 recall records (0 Class I) 2019: 0 inspections (0 OAI), 0 warning letters, 1 recall record (0 Class I) 2020: 0 inspections (0 OAI), 0 warning letters, 0 recall records (0 Class I) 2021: 0 inspections (0 OAI), 0 warning letters, 0 recall records (0 Class I) 2022: 0 inspections (0 OAI), 0 warning letters, 2 recall records (0 Class I) 2023: 0 inspections (0 OAI), 0 warning letters, 0 recall records (0 Class I) 2024: 0 inspections (0 OAI), 0 warning letters, 0 recall records (0 Class I) 2025: 0 inspections (0 OAI), 0 warning letters, 0 recall records (0 Class I) 2026: 0 inspections (0 OAI), 0 warning letters, 0 recall records (0 Class I)
YearInspectionsOAIWarning lettersRecall recordsClass I
202600000
202500000
202400000
202300000
202200020
202100000
202000000
201900010
201800030
201700020

Inspections are counted by the date they ended, warning letters by the date FDA issued them and recall records by the recall start date. FDA lists one recall record per recalled product, so one recall event can add several.

Reviewing Mylan Institutional, Inc. (D.B.A. UDL Laboratories) as a supplier? Request a free FDA snapshot: name up to five suppliers and get a PDF of their public FDA record, with sources and dates. You do not need an API connection. Each snapshot is prepared by hand.

Check this supplier

Or check Mylan Institutional, Inc. (D.B.A. UDL Laboratories) yourself in Claude, Cursor or ChatGPT: get the full FDA risk summary, with inspections, warning letters, Form 483s and import alerts by site.

Get a free API key

Recent recalls

22 recall records from Dec 14, 2012 to Apr 1, 2022. Showing the 20 most recent. View all 22 recall records

NumberClassProductDate
D-0860-2022Class IIEsomeprazole Magnesium Delayed-Release Capsules, USP 20 mg, packaged in Unit Dose Blister Cards of 6…Apr 1, 2022
D-0861-2022Class IIEsomeprazole Magnesium Delayed-Release Capsules, USP 40 mg, packaged in Unit Dose Blister Cards of 6…Apr 1, 2022
D-1013-2019Class IIAlprazolam Tablets, USP, 0.25 mg, 10x10 per carton, Rx Only, Manufactured for: Mylan Pharmaceuticals…Jan 18, 2019
D-1112-2018Class IIIDiltiazem HCl Extended-release Capsules, USP 120 mg, 80 capsules, 8 blister cards of 10 capsules…Aug 14, 2018
D-0823-2018Class IILoxapine Capsules, USP 50 mg, packaged in 100 Unit Dose capsules, Rx only, Manufactured by Mylan…May 1, 2018
D-0822-2018Class IILoxapine Capsules, USP 25 mg, packaged in 100 Unit Dose Capsules, Rx only, Manufactured by Mylan…May 1, 2018
D-0622-2017Class IIAtorvastatin Calcium Tablets, 10 mg*, 100-count Unit Dose Tablets (10 x 10) per carton, Rx only…Mar 21, 2017
D-0493-2017Class IIMirtazapine Tablets, USP, 45 mg. Rx only, 100 Tablets (10 X 10). Manufactured by: Mylan…Jan 27, 2017
D-0136-2017Class IIIClonazepam Tablets, USP, 1.0 mg, packaged in a 100- count unit dose box of 10 x 10 blister cards, Rx…Sep 28, 2016
D-0135-2017Class IIIClonazepam Tablets, USP, 0.5 mg, packaged in a)100- count unit dose box of 10 x 10 blister cards…Sep 28, 2016
D-0650-2016Class IIIClonazepam Tablets, USP, 0.5 mg, 100-count carton, Rx only, Manufactured by Mylan Pharmaceuticals…Jan 28, 2016
D-0235-2016Class IIIMeclizine Hydrochloride Tablets, USP, 25 mg Tablets, Packaged in 10 x 10 Tablet Blister Pack…Nov 2, 2015
D-1083-2015Class IIIFexofenadine Hydrochloride Tablets, USP 60 mg, Allergy, Non-Drowsy, Antihistamine, 100 tablets (10 X…Mar 26, 2015
D-1435-2014Class IIIDiltiazem HCl Extended-release Capsules, USP, 120 mg, packaged in 80 Capsules (8 x 10) blister cards…Jul 3, 2014
D-1155-2014Class IIICarisoprodol Tablets, USP, 350 mg, unit dose blister packages of 100 tablets (10 cards of 10 tablets…Jan 28, 2014
D-0378-2015Class IILAMOTRIGINE TABLETS, 200 mg, 100 Tablets (10 tablets per blister card x 10 blister cards per…Sep 26, 2013
D-0377-2015Class IICIPROFLOXACIN TABLETS, USP, 500 mg, 100 Tablets (10 tablets per blister card. 10 blister cards per…Sep 26, 2013
D-1466-2016Class IIAmlodipine Besylate Tablets, USP, 2.5 mg*, packaged in a)100-count (10 x 10) unit dose blisters per…Sep 17, 2013
D-1468-2016Class IIAmlodipine Besylate Tablets, USP, 10 mg*, packaged in a) 100-count (10 x 10) unit dose blisters per…Sep 17, 2013
D-1467-2016Class IIAmlodipine Besylate Tablets, USP, 5 mg*, packaged in a) 100-count (10 x 10) unit dose blisters per…Sep 17, 2013

Mylan Institutional, Inc. (D.B.A. UDL Laboratories) and the FDA: common questions

Has Mylan Institutional, Inc. (D.B.A. UDL Laboratories) received an FDA warning letter?

No FDA warning letter addressed to the name "Mylan Institutional, Inc. (D.B.A. UDL Laboratories)" is on file. This answer covers that name only: letters addressed to a related company name or to one of its sites are listed on that name's or site's own page.

Has Mylan Institutional, Inc. (D.B.A. UDL Laboratories) received an FDA Form 483?

FDA has not published a Form 483 for "Mylan Institutional, Inc. (D.B.A. UDL Laboratories)" in its reading room. FDA publishes some Form 483s, not all of them.

Has Mylan Institutional, Inc. (D.B.A. UDL Laboratories) had an FDA recall?

Yes. Mylan Institutional, Inc. (D.B.A. UDL Laboratories) has 22 FDA recalls on record, 1 of them Class I, the most serious class. The most recent started Apr 1, 2022.

Need more than this page shows? Ask about Mylan Institutional, Inc. (D.B.A. UDL Laboratories) in Claude or ChatGPT and get every site's inspections, Form 483s, warning letters and import alerts, with a link to the FDA source for each record. The API key is free: no card.

Get a free API key

Prefer a PDF? Request a free supplier snapshot.

Is this your company or a supplier you list? Link to this FDA record from your site with a free button.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.